NEW YORK, June 13 – Nanogen said Wednesday that its chief technical officer and a company co-founders, Michael Heller, was leaving his position to take a job as a professor at an unnamed university.

"We are grateful for Dr. Heller's outstanding contributions to Nanogen over his approximately nine years here," Howard Birndorf, chairman of Nanogen’s board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.